Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR10391(B)] to Lunatic Fringe
- Suitable for: WB, Flow Cyt
- Reacts with: Mouse, Rat, Human
Product nameAnti-Lunatic Fringe antibody [EPR10391(B)]
See all Lunatic Fringe primary antibodies
DescriptionRabbit monoclonal [EPR10391(B)] to Lunatic Fringe
Tested applicationsSuitable for: WB, Flow Cytmore details
Unsuitable for: ICC,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide, corresponding to residues in Human Lunatic Fringe (UniProt: Q8NES3).
- PC12, HeLa and K562 cell lysates; K562 cells.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab151699 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 42 kDa.|
|Flow Cyt||1/10 - 1/100.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
FunctionGlycosyltransferase that initiates the elongation of O-linked fucose residues attached to EGF-like repeats in the extracellular domain of Notch molecules. Decreases the binding of JAGGED1 to NOTCH2 but not that of DELTA1. Essential mediator of somite segmentation and patterning.
Involvement in diseaseDefects in LFNG are the cause of spondylocostal dysostosis type 3 (SCDO3) [MIM:609813]. An autosomal recessive condition of variable severity associated with vertebral and rib segmentation defects. The main skeletal malformations include fusion of vertebrae, hemivertebrae, fusion of certain ribs, and other rib malformations. Deformity of the chest and spine (severe scoliosis, kyphoscoliosis and lordosis) is a natural consequence of the malformation and leads to a dwarf-like appearance. As the thorax is small, infants frequently have respiratory insufficiency and repeated respiratory infections resulting in life-threatening complications in the first year of life.
Sequence similaritiesBelongs to the glycosyltransferase 31 family.
modificationsA soluble form may be derived from the membrane form by proteolytic processing.
Cellular localizationGolgi apparatus membrane.
- Information by UniProt
- 3-N-acetylglucosaminyltransferase lunatic fringe antibody
- Beta-1 antibody
- Beta-13-N-acetylglucosaminyltransferase lunatic fringe antibody
All lanes : Anti-Lunatic Fringe antibody [EPR10391(B)] (ab151699) at 1/1000 dilution
Lane 1 : PC12 cell lysate
Lane 2 : HeLa cell lysate
Lane 3 : K562 cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 42 kDa
Flow cytometric analysis of permeabilized K562 cells labeling Lunatic Fringe with ab151699 at 1/10 dilution (red) compared to a nonspecific control antibody (green).
ab151699 has not yet been referenced specifically in any publications.